Articles

HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia

Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy;Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy;Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy;Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Department of Oncology, University of Turin, Turin, Italy
Department of Oncology, University of Turin, Turin, Italy
Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy;Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Clinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy
Clinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy
Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
Department of Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland
Department of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Trieste, Italy
Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Hematology Day Service, Oncology SOC, Hospital Cardinal Massaia, Asti, Italy
Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy
Hematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Rome, Italy
Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland
Clinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Hematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Rome, Italy
Hematology Unit, ASO Santa Croce e Carle, Cuneo, Italy
Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy;Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy;Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
Vol. 105 No. 4 (2020): April, 2020 https://doi.org/10.3324/haematol.2019.217430